KARO BIO
DEAD

Serial Number

76311857

Owner

KARO BIO AB

Attorney

Mainak H. Mehta

Filing Date

Sep 12, 2001

Add to watchlist:

No watchlists yet
View on USPTO

KARO BIO Trademark

Serial Number: 76311857 • Registration: 2950803

KARO BIO is a trademark filed by KARO BIO AB on September 12, 2001. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KARO BIO AB (8 trademarks)

57 HUDDINGE
NOVUM, S-141 , SE

Entity Type: 03

Trademark Details

Filing Date

September 12, 2001

Registration Date

May 17, 2005

Published for Opposition

November 30, 2004

Cancellation Date

November 28, 2025

Goods & Services

Chemical reagents for scientific or research use, namely, assays for identification of compounds that bind and/or modulate one or more biologically active substances, such as receptors and enzymes, assays for the identification of the biological activity of biologically active substances, such as enzymes or receptors, assays for the identification of antibacterial compounds, compounds capable of modulating the biological activity of a biologically active substance, such as an enzyme or a receptor, and tissue culture growth media; chemical preparations for use in medical research, namely, reagents for the identification of compounds that bind and/or modulate one or more biologically active substances, such as receptors and enzymes, assays for the identification of the biological activity of biologically active substances such as enzymes or receptors; assays for the identification of antibacterial compounds, compounds capable of modulating the biological activity of a biologically active substance, such as an enzyme or a receptor; biochemicals for industrial purposes, namely, tissue culture growth media; chemical and biological substances for use in the manufacture of medicinal, pharmaceutical and veterinary products

Pharmaceutical preparations for the treatment of metabolic disorders such as diabetes, obesity and hypercholesterolemia, cardiovascular diseases, congenital heart failure, cardiac arrhythmia, atrial fibrillation and hypertension, osteoporosis, menopause, puberty and urogenital atrophy, male hormone deficiency, cancer, ophthalmology, skin disorders, inflammatory disorders and bacterial infections; pharmaceutical substances, namely dermatological creams for the treatment of skin disorders; veterinary preparations for the treatment of metabolic disorders such as diabetes, obesity and hypercholesterolemia, cardiovascular diseases, congenital heart failure, cardiac arrhythmia, atrial fibrillation and hypertension, osteoporosis, menopause, puberty and urogenital atrophy, male hormone deficiency, cancer, ophthalmology, skin disorders, inflammatory disorders and bacterial infections; veterinary substances, namely, dermatological creams for use in the treatment of skin disorders, medicinal preparations for the treatment of metabolic disorders such as such as diabetes, obesity and hypercholesterolemia, cardiovascular diseases, congenital heart failure, cardiac arrhythmia, atrial fibrillation and hypertension, osteoporosis, menopause, puberty and urogenital atrophy, male hormone deficiency, cancer, ophthalmology, skin disorders, inflammatory disorders and bacterial infections; medicinal substances, namely, dermatological cream for the treatment of skin disorders; medical diagnostic reagents; diagnostic agents for veterinary use; clinical medical reagents, namely, reagents for clinical-chemical tests; diagnostic reagents for clinical or medical laboratory use; vaccines; transdermal drug patches sold with medication for the treatment of metabolic disorders such as diabetes, obesity and hypercholesterolemia, cardiovascular diseases, congenital heart failure, cardiac arrhythmia, atrial fibrillation and hypertension, stroke, peripheral vascular disease, thromboembolism, retenosis of catheterization or surgical repairs, osteoporosis, menopause, puberty and urogenital atrophy, male hormone deficiency, cancer, ophthalmology, skin disorders, inflammatory disorders and bacterial infections; diagnostic kits for medical and veterinary purposes, namely, assays and reagents for the identification of compounds that bind and/or modulate one or more biologically active substances, such as receptors and enzymes, for the identification of the biological activity of biologically active substances, such as enzymes and receptors and to identify antibacterial compounds

[Diagnostic apparatus for medical and veterinary purposes, namely, apparatus used in identifying compounds that bind and/or modulate one or more biologically active substances, such as receptors and enzymes, for the identification of the biological activity or biologically active substances, such as receptors and enzymes, and to identify antibacterial compounds]

Pharmaceutical research services; pharmaceutical advisory services; scientific research project management; scientific and industrial research; medical laboratory services; medical research; provision of medical information; veterinary laboratory services

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Nov 28, 2025 CAEX
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
May 17, 2024 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 13, 2015 NAS8
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 13, 2015 RNL1
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Jun 13, 2015 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Jun 13, 2015 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 13, 2015 APRE
TEAS SECTION 8 & 9 RECEIVED
May 23, 2015 E89R
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 5, 2012 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 5, 2012 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 5, 2012 APRE
TEAS SECTION 8 & 15 RECEIVED
Nov 17, 2011 E815
REGISTERED-PRINCIPAL REGISTER
May 17, 2005 R.PR
NOTICE OF ALLOWANCE CANCELLED
Apr 7, 2005 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Apr 4, 2005 D1BR
NOA MAILED - SOU REQUIRED FROM APPLICANT
Feb 22, 2005 NOAM
PUBLISHED FOR OPPOSITION
Nov 30, 2004 PUBO
NOTICE OF PUBLICATION
Nov 10, 2004 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 29, 2004 PREV
ASSIGNED TO LIE
Sep 24, 2004 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 20, 2004 CNSA
EXAMINERS AMENDMENT MAILED
Sep 16, 2004 CNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 15, 2004 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Aug 13, 2004 ZZZX
SEC. 44(D) CLAIM DELETED
Jun 24, 2004 44DD
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 18, 2004 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 21, 2004 CRFA
PAPER RECEIVED
May 21, 2004 MAIL
INQUIRY AS TO SUSPENSION MAILED
Feb 9, 2004 CNSI
LETTER OF SUSPENSION MAILED
Jul 3, 2003 CNSL
CASE FILE IN TICRS
May 23, 2003 CFIT
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 14, 2003 CRFA
LETTER OF SUSPENSION MAILED
Apr 14, 2003 CNSL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2003 CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 25, 2003 CRFA
LETTER OF SUSPENSION MAILED
Feb 25, 2003 CNSL
ASSIGNED TO EXAMINER
Feb 24, 2003 DOCK
PAPER RECEIVED
Dec 23, 2002 MAIL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 4, 2002 CRFA
NON-FINAL ACTION MAILED
Nov 28, 2001 CNRT
ASSIGNED TO EXAMINER
Nov 15, 2001 DOCK